Journal of Kidney Cancer and VHL

Scope & Guideline

Connecting researchers for impactful kidney cancer solutions.

Introduction

Delve into the academic richness of Journal of Kidney Cancer and VHL with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2203-5826
PublisherCODON PUBLICATIONS
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationJ KIDNEY CANCER VHL / J. Kidney Cancer VHL
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressLEVEL 9, 167 EAGLE ST, BRISBANE, QLD 4000, AUSTRALIA

Aims and Scopes

The Journal of Kidney Cancer and VHL focuses on disseminating significant research and findings related to kidney cancers, particularly emphasizing the genetic and clinical aspects associated with renal cell carcinoma and von Hippel-Lindau (VHL) disease. The journal aims to bridge clinical practice and research, providing insights into diagnosis, treatment, and management strategies.
  1. Kidney Cancer Research:
    The journal primarily publishes studies and reviews that explore various aspects of kidney cancer, including epidemiology, pathology, and treatment outcomes.
  2. VHL Disease Insights:
    A specialized focus on von Hippel-Lindau disease, including its genetic implications, associated tumors, and clinical management.
  3. Surgical Techniques and Outcomes:
    Research on different surgical modalities for kidney cancer treatment, including partial and radical nephrectomy, emphasizing innovative techniques and their outcomes.
  4. Clinical Trials and Patient Management:
    The journal discusses findings from clinical trials, especially regarding the management of metastatic renal cell carcinoma and the efficacy of new therapeutic agents.
  5. Case Reports and Reviews:
    Publication of unique case reports and comprehensive reviews that enhance understanding of rare presentations of kidney cancers and their management.
  6. Emerging Therapeutic Strategies:
    Exploration of novel treatment approaches, including immunotherapy and targeted therapy, particularly for advanced and metastatic kidney cancers.
Recent trends in the Journal of Kidney Cancer and VHL indicate a growing interest in specific themes that reflect the evolving landscape of kidney cancer research and treatment. These emerging areas highlight the journal's responsiveness to new challenges and advancements in the field.
  1. Genomic and Transcriptomic Studies:
    An increasing number of publications focus on the genomic and transcriptomic characteristics of kidney cancers, reflecting a trend towards personalized medicine and targeted therapies.
  2. Metastatic Renal Cell Carcinoma Management:
    There is a heightened emphasis on the management of metastatic renal cell carcinoma, including active surveillance strategies, which is crucial given the complexity of treatment options in this patient population.
  3. Innovations in Surgical Techniques:
    Emerging trends include comparative studies of surgical techniques, particularly minimally invasive approaches, highlighting advancements in surgical oncology for kidney cancer.
  4. Palliative Care and Quality of Life:
    A growing number of studies are addressing the role of palliative care in kidney cancer management, focusing on the impact of treatment on patients’ quality of life and symptom management.
  5. Interdisciplinary Approaches:
    Research increasingly emphasizes interdisciplinary approaches that integrate surgical, medical, and supportive care perspectives, reflecting a holistic view of kidney cancer management.

Declining or Waning

While the journal has maintained a strong focus on various aspects of kidney cancer and VHL, certain themes appear to be declining in prominence over recent years, reflecting shifts in research priorities or advancements in treatment methodologies.
  1. Basic Science Research:
    There has been a noticeable decrease in publications focused on the fundamental biological and molecular mechanisms underlying kidney cancer, possibly due to a shift towards translational and clinical research.
  2. Radiological Imaging Studies:
    Fewer articles are being published that solely focus on imaging techniques for kidney cancer diagnosis, suggesting a shift towards more integrated approaches that combine clinical and molecular data.
  3. Historical Case Studies:
    The journal has seen a decline in the number of historical case studies or retrospective analyses, which may indicate a move towards more innovative and prospective research designs.

Similar Journals

Molecular and Clinical Oncology

Connecting researchers to revolutionize cancer treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Case Reports in Nephrology and Dialysis

Innovative case studies shaping the future of nephrology.
Publisher: KARGERISSN: 2296-9705Frequency: 3 issues/year

Case Reports in Nephrology and Dialysis, published by KARGER, is a vital peer-reviewed journal dedicated to the dissemination of case reports and innovative findings in the fields of nephrology and dialysis. Since its inception in 2015, this Open Access journal has aimed to foster knowledge exchange and improve patient outcomes through comprehensive case studies, clinical insights, and recent advancements in renal healthcare. Based in Switzerland, the journal is poised to serve a global audience, accommodating research that spans diverse geographical and clinical contexts. Currently ranked in the Q3 category for nephrology in 2023, it underscores its burgeoning influence in the medical literature, despite its relatively nascent presence. As a valuable resource for researchers, healthcare professionals, and students, it provides a platform for sharing unique cases that enrich the understanding of complex renal issues and challenges faced in dialysis. With an emphasis on high-quality, accessible research, Case Reports in Nephrology and Dialysis is committed to advancing nephrology and dialysis practices through collaboration and knowledge sharing.

Clinical Genitourinary Cancer

Exploring breakthroughs in cancer treatment and management.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Case Reports in Oncological Medicine

Innovating cancer treatment through real-world experiences.
Publisher: HINDAWI LTDISSN: 2090-6706Frequency: 1 issue/year

Case Reports in Oncological Medicine is a distinguished open-access journal published by HINDAWI LTD, dedicated to disseminating valuable insights and findings in the field of oncology. Since its inception in 2011, this journal has aimed to provide a unique platform for the publication of detailed case reports that contribute to our understanding of cancer diagnosis, treatment, and management. With a specific focus on sharing clinical experiences and outcomes, it seeks to engage researchers, healthcare professionals, and students who are committed to advancing oncological knowledge and improving patient care. Although coverage in Scopus was discontinued from 2014 to 2017, the journal currently holds a rank of #232/323 in Medicine - Oncology, placing it within the 28th percentile. Researchers interested in making their work accessible can benefit from the journal's open-access model, allowing greater visibility and citation potential within the scientific community. The journal is positioned as an important resource for those looking to stay updated on the latest case studies and innovations in oncological medicine.

NEPHROLOGY

Exploring innovative solutions in nephrology and medicine.
Publisher: WILEYISSN: 1320-5358Frequency: 12 issues/year

NEPHROLOGY is a leading academic journal published by Wiley, dedicated to advancing research and discussions in the fields of Nephrology and Medicine. With an ISSN of 1320-5358, this journal has consistently demonstrated its significance and impact, reflecting a Q2 category ranking in both Medicine (miscellaneous) and Nephrology as of 2023. Covering a comprehensive range of topics since its inception in 1995, NEPHROLOGY provides a vital platform for researchers, practitioners, and students alike to explore the latest advancements, innovative treatments, and diverse challenges within the field. Although it does not operate under an open access model, the journal remains highly regarded, with a commendable Scopus rank of #27 out of 81 in Nephrology, positioning it in the 67th percentile among its peers. Located in the United Kingdom, NEPHROLOGY invites submissions that push the boundaries of knowledge, ultimately striving to enhance the understanding of renal health and disease.

Clinical Lung Cancer

Transforming knowledge into practice in lung cancer treatment.
Publisher: CIG MEDIA GROUP, LPISSN: 1525-7304Frequency: 6 issues/year

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Leukemia Research Reports

Fostering collaboration for a leukemia-free future.
Publisher: ELSEVIER ADVANCED TECHNOLOGYISSN: 2213-0489Frequency: 2 issues/year

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

Renal Replacement Therapy

Bridging disciplines for a healthier future in renal care.
Publisher: BMCISSN: Frequency: 1 issue/year

Renal Replacement Therapy is an esteemed open-access journal published by BMC, dedicated to advancing the field of nephrology, transplantation, and urology. Established in 2015, the journal aims to disseminate high-quality research findings to enhance the understanding and management of kidney-related diseases and therapies. Renal Replacement Therapy is ranked in the third quartile (Q3) in the categories of Nephrology, Transplantation, and Urology as of 2023, reflecting its growing influence and commitment to academic excellence. The journal encourages interdisciplinary study and collaboration, welcoming contributions from researchers, clinicians, and healthcare professionals. With a focus on practical applications and innovative therapies, this journal is instrumental for those seeking the latest insights and advancements in renal replacement strategies. Located in the United Kingdom, the journal strives to provide unparalleled access to critical research, ensuring that its findings are available to a global audience striving to improve patient outcomes in renal health.

European Urology Oncology

Elevating the standards of urological oncology research.
Publisher: ELSEVIERISSN: Frequency: 6 issues/year

European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.

Hematology Reports

Unlocking the future of hematology research.
Publisher: MDPIISSN: 2038-8322Frequency: 4 issues/year

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.